Phase 4
Completed N=56
Ketamine and Propofol for Upper Endoscopy
Anesthesia
Source: ClinicalTrials.gov NCT02295553 ↗
Enrolled (actual)
56
Serious AEs
0.0%
Results posted
Jun 2019
Primary outcomePrimary: Dose of Propofol Required to Prevent Movement (Response) to Insertion of Endoscope Into the Patient's Esophagus — 6.1; 4.5; 4.7; 1.1 mg/kg
◆ Published Evidence
Established
28citations · ~4 / year
Determination of the median effective dose of propofol in combination with different doses of ketamine during gastro-duodenoscopy in children: a randomised controlled trial.
Summary
The purpose of this study is to examine the dose-response relationship of ketamine in combination with propofol.
Linked Publications
-
Determination of the median effective dose of propofol in combination with different doses of ketamine during gastro-duodenoscopy in children: a randomised controlled trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Dose of Propofol Required to Prevent Movement (Response) to Insertion of Endoscope Into the Patient's Esophagus |
6.1; 4.5; 4.7; 1.1 | — |
| SECONDARY Duration of Apnea After Propofol Administration |
59; 45; 57; 39 | — |
| SECONDARY Incidence of Adverse Respiratory Events During the Procedure |
11; 10; 11; 9; 1; 1 | — |
| SECONDARY Incidence of Side Effects and Complications During the Recovery Period |
0; 0; 1; 0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Age 3-13 years
- Receiving general anesthesia for upper endoscopy
Exclusion Criteria
- Known or possible difficult airway
- BMI > 35
- Weight < 10 kg
- Sedative premedication required
- Known contraindication to ketamine or propofol
Data sourced from ClinicalTrials.gov (NCT02295553) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.